DK0793962T3 - Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans - Google Patents

Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans

Info

Publication number
DK0793962T3
DK0793962T3 DK96830093T DK96830093T DK0793962T3 DK 0793962 T3 DK0793962 T3 DK 0793962T3 DK 96830093 T DK96830093 T DK 96830093T DK 96830093 T DK96830093 T DK 96830093T DK 0793962 T3 DK0793962 T3 DK 0793962T3
Authority
DK
Denmark
Prior art keywords
treatment
product containing
arteriosclerosis obliterans
medicinal product
carnitine derivative
Prior art date
Application number
DK96830093T
Other languages
English (en)
Inventor
Marco Corsi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK0793962T3 publication Critical patent/DK0793962T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DK96830093T 1996-03-04 1996-03-04 Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans DK0793962T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96830093A EP0793962B1 (en) 1996-03-04 1996-03-04 Medicament containing a carnitine derivative for treating arteriosclerosis obliterans

Publications (1)

Publication Number Publication Date
DK0793962T3 true DK0793962T3 (da) 2000-05-22

Family

ID=8225823

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96830093T DK0793962T3 (da) 1996-03-04 1996-03-04 Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans

Country Status (13)

Country Link
US (1) US5811457A (da)
EP (1) EP0793962B1 (da)
JP (1) JPH09323927A (da)
KR (1) KR100346883B1 (da)
AT (1) ATE187329T1 (da)
CA (1) CA2198833C (da)
DE (1) DE69605531T2 (da)
DK (1) DK0793962T3 (da)
ES (1) ES2141463T3 (da)
GR (1) GR3032903T3 (da)
PT (1) PT793962E (da)
TW (1) TW349863B (da)
ZA (1) ZA971808B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
CA2350071A1 (en) * 1998-11-11 2000-05-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
AU1258699A (en) * 1998-11-11 2000-05-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
ITRM20010708A1 (it) 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
EP1496054A1 (en) * 2002-04-18 2005-01-12 Chugai Seiyaku Kabushiki Kaisha Medicinal composition for improving angiotension-regulating function of blood vessel endothelium
US7776913B2 (en) * 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006061341A1 (en) * 2004-12-10 2006-06-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a high-dose medicament for the treatment of peripheral arterial disease
US7560485B2 (en) * 2005-10-04 2009-07-14 Sigma-Tau Industrie Parmaceutiche Riunite S.P.A. Method for treating intermittent claudication comprising the administration of propionyl L-carnitine and a concomitant physical training
EP2353596A1 (en) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
SG185692A1 (en) 2010-06-16 2013-01-30 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
US9114120B2 (en) 2010-11-22 2015-08-25 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Therapeutical method for the treatment of the Leber optic neuropathy
US20140294921A1 (en) 2010-12-09 2014-10-02 Sigma-Tau Industrie Famaceutiche Riunite S.P.A. Composition for tipical use for treating skin disorders
EP2783695A1 (en) 2013-03-28 2014-10-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Physiological supplement or medicament for ophthalmic use containing L-carnitine or alkanoyl L-carnitines in combination with eledoisin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease

Also Published As

Publication number Publication date
DE69605531T2 (de) 2000-05-31
US5811457A (en) 1998-09-22
ATE187329T1 (de) 1999-12-15
EP0793962A1 (en) 1997-09-10
ZA971808B (en) 1998-07-31
JPH09323927A (ja) 1997-12-16
GR3032903T3 (en) 2000-07-31
KR100346883B1 (ko) 2003-01-06
KR970064602A (ko) 1997-10-13
PT793962E (pt) 2000-05-31
ES2141463T3 (es) 2000-03-16
CA2198833C (en) 2003-07-22
EP0793962B1 (en) 1999-12-08
TW349863B (en) 1999-01-11
MX9701294A (es) 1997-09-30
CA2198833A1 (en) 1997-09-04
DE69605531D1 (de) 2000-01-13

Similar Documents

Publication Publication Date Title
DK0793962T3 (da) Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans
DK0773020T3 (da) Farmaceutiske præparater indeholdende L-carnitin eller derivater deraf i kombination med resveratrol eller derivater deraf til forebyggelsen og behandlingen af cardiovaskulære lidelser, perifere vaskulære sygdomme og perifer diabetisk neuropati
DE69629273D1 (de) Zusammensetzungen enthaltend Propionyl-L-Carnitine und Hydroxyzitronensäure oder Pantothensäure
DE69402343T2 (de) Katheter- und Nadeleinrichtung zum Verabreichen therapeutischer Lösungen
NO981911D0 (no) Anvendelse av rhodaninderivater for fremstilling av et medikament for behandling av Alzheimer's sykdom
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
NO975234L (no) Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
DK0498144T3 (da) Anvendelse af acetyl-L-carnitin ved terapeutisk behandling af coma
NO944339L (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
AU670491C (en) Pharmaceutical for the treatment of skin disorders
BR9608595A (pt) Utilização de n-cicloexil benzamidas para o tratamento de aglições intestinais
EA199900862A1 (ru) Способ лечения сосудистых нарушений
NO920640L (no) Anordning for terapeutisk trykkbehandling
FI953725A (fi) Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
FI933872A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4h)-on-derivat
IT9067177A0 (it) Mezzi per il trattamento terapeutico dell'apnea durante il sonno
DK0671910T3 (da) Anvendelse af adamantanderivater til fremstilling af et lægemiddel til behandling af glaucoma
ITMI920898A0 (it) Apparecchiatura a raggi ultravioletti per la cura mirata di patologie dermatologiche
FI951041A (fi) (S)-(-)-alfa-etyyli-2-okso-1-pyrrolidiiniasetamidin käyttö valmistettaessa farmaseuttinen valmiste ahdistuksen hoitoon